Profound Medical CorpNASDAQ:PROFView on Canadian Exchange
- LAST PRICE7.6800
- TODAY'S CHANGE (%)0.1600 (2.1277%)
- Bid / Lots7.5800/ 2
- Ask / Lots7.7900/ 2
- Open / Previous Close7.7900 / 7.5200
- Day Range
- 52 Week Range
- Volume17,298
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PROF |
|---|---|---|
| 09:32 ET | 715 | 7.79 |
| 10:00 ET | 5400 | 7.83 |
| 10:11 ET | 100 | 7.82 |
| 10:18 ET | 400 | 7.68 |
| 10:20 ET | 1000 | 7.62 |
| 10:26 ET | 747 | 7.68 |
| 10:29 ET | 3917 | 7.81 |
| 10:31 ET | 2996 | 7.685 |
| 10:38 ET | 100 | 7.685 |
| 10:49 ET | 100 | 7.685 |
| 11:02 ET | 400 | 7.68 |
Today
Nov 12, 2024
Profound Medical to Participate in the Stifel 2024 Healthcare Conference, from 8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 7, 2024
Profound Medical Announces Third Quarter 2024 Financial Results, from 4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 4, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Profound Medical Corp | 261.8M | 0.0x | --- |
Company Information
Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low -, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Contact Information
- Headquarters
- 2400 Skymark Ave Unit 6MISSISSAUGA, ON, Canada L4W 5K5
- Phone
- 647-476-1350
- Fax
- 647-476-1350
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $261.8M |
|---|---|
Revenue (TTM) | $12.6M |
Shares Outstanding | 24.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.87 |
EPS | $-1.87 |
Book Value | $2.04 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 20.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -368.27% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
